Summary
New pharmacological treatments for opioid dependence include detoxification agents such as clonidine and lofexidine, and maintenance agents such as levacetylmethadol (levo-α-acetylmethadol; LA AM) and buprenorphine. Detoxification from opioids has been facilitated by the development of clonidine, particularly in combination with naltrexone. New experimental approaches have also been tried to reduce the time that it takes to complete the process of detoxification or to further reduce residual withdrawal symptoms not completely relieved by clonidine. Maintenance on levacetylmethadol or buprenorphine has become a viable alternative to methadone maintenance and holds promise for the future.
Similar content being viewed by others
References
Wodak A. Managing illicit drug use: a practical guide. Drugs 1994; 47: 446–57
Stimson GV. The global diffusion of injecting drug use: implications for human immunodeficiency virus infection. Bull Narc 1993; 45: 3–17
Wodak A, Crofts N, Fisher R. HIV infection among injecting drug users in Asia: an evolving public health crisis. AIDS Care 1993; 5: 313–20
Alvarez L. The middle class rediscovers heroin. NY Times 1995; Aug 14
Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150: 97–9
Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 1995; 245: 114–24
Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West J Med 1990; 152: 588–99
Koob GF, Maldonado R, Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992; 15: 186–91
Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992; 12: 2439–50
Redmond DE, Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. Ann Rev Neurosci 1984; 7: 443–78
Kleber HD, Riordan CE, Rounsaville BJ, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985; 42: 391–4
Rounsaville BJ, Kosten TR, Kleber HD. Success and failure at outpatient opioid detoxification: evaluating the process of clonidine and methadone-assisted withdrawal. J Nerv Ment Dis 1985; 173: 103–10
Aghajanian GK. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 1978; 276: 186–8
Taylor JR, Elsworth JD, Garcia EJ, et al. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology 1988; 96: 121–34
Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978; II: 599–602
Gold MS, Redmond Jr DE, Kleber HD. Clonidine in opiate withdrawal. Lancet 1978; I: 929–30
Gold MS, Pottash AC, Sweeney DR, et al. Opiate withdrawal using clonidine. JAMA 1980; 243: 343–6
Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry 1981; 38: 1273–7
Uhde TW, Redmond Jr DE, Kleber HD. Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. Psychiatry Res 1980; 2: 37–47
Washton AM, Resnick RB. Clonidine for opiate detoxification: outpatient clinical trial. Am J Psychiatry 1980; 137: 1121–2
Kleber HD, Kosten TR. Naltrexone induction: psychologic and pharmacologic strategies. J Clin Psychiatry 1984; 45: 29–38
Washton AM, Resnick RB. Clonidine vs methadone for opiate detoxification: double-blind outpatient trials. NIDA Res Monogr 1981; 34: 89–94
Cami J, de Torres S, San L, et al. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clin Pharmacol Ther 1985; 38(3): 336–41
Ghodse H, Myles J, Smith S. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br J Psychiatry 1994; 165: 370–4
Blachley PH. Naloxone for diagnosis in methadone programs. JAMA 1973; 244: 334–5
Charney DS, Riordan CE, Kleber HD, et al. Clonidine and naltrexone: a safe, effective and rapid treatment of abrupt withdrawal from methadone. Arch Gen Psychiatry 1982; 39: 1327–32
Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 1986; 143: 831–7
Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13: 1–17
Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. Br J Psychiatry 1988; 153: 340–3
Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 1988; 83: 567–75
Azatian A, Papiasvilli A, Joseph H. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Dis 1994; 13: 35–52
O’Connor PG, Waugh ME, Schottenfeld RS, et al. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J Gen Intern Med 1992; 7: 532–4
Shearman GT, Lai H, Ursillo RC. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol Biochem Behav 1980; 12: 573–5
Gold MS, Pottash AC, Sweeney DR, et al. Lofexidine blocks acute opiate withdrawal. NIDA Res Monogr 1982; 41: 264–8
Washton AM, Resnick RB, Perzel JF, et al. Opiate detoxification using lofexidine. NIDA Res Monogr 1982; 41: 261–3
Wylie AS, Stewart AM. Lofexidine based regimen for opiate addicts [letter], Br J Gen Pract 1995; 45: 217–8
Wilkins LH, Winternitz SR, Oparil S, et al. Lofexidine and clonidine in moderate essential hypertension. Clin Pharmacol Ther 1981; 20: 752–7
Cox S, Alcorn R. Lofexidine and opioid withdrawal [letter]. Lancet 1995; 345: 1385–6
Doxey JC. Pre- and postsynaptic effects of α-agonists in the anococcygeus muscle of the pithed rat. Eur J Pharmacol 1979; 54: 185–9
Schubert H, Fleischhacker WW, Meise U, et al. Preliminary results of guanfacine treatment of acute opiate withdrawal. Am J Psychiatry 1984; 141: 1271–3
Muga R, Tor J, Forteza-Rei J, et al. Comparative effectiveness of alpha-2 adrenergic agonists (clonidine-guanfacine) in the hospital detoxification of opiate addicts [in Spanish]. Med Clin (Bare) 1990; 94: 169–72
San L, Fernández T, Cami J, et al. Efficacy of methadone vs methadone and guanfacine in the detoxification of heroin-addicted patients [abstract]. Neuropschychopharmacology 1994; 10: 130S
Jasinski D, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 510–6
Preston KL, Jasinski DR. Abuse liability of opioid agonist-antagonists in humans. Drug Alcohol Depend 1991; 28: 49–82
Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36: 115–21
Janiri L, Mannelli P, Persico AM, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994; 36: 139–45
O’Connor P, Waugh ME, Weiss EC, et al. A comparison of clonidine, clonidine/naltrexone, and buprenorphine in primary care-based ambulatory opioid detoxification [abstract]. Clin Res 1993; 41: 545A
Kosten TR, Schottenfeld R, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181: 358–64
Loimer N, Lenz K, Schmid R, et al. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 1991; 148: 933–5
Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 80–4
Senay EC, Dorus W, Goldberg F, et al. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry 1977; 34: 361–7
Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag, 1991: 212–32
Archer S. Preclinical studies: pharmacology of LAAM in Rx: 3x/week LAAM - alternative to methadone. NIDA Res Monogr 1976; 8: 15–28
Eddy NB, Touchberry CF, Lieberman JE, et al. Synthetic analgesics: methadone isomers and derivatives. J Pharmacol Exp Ther 1950; 98: 121–37
Keats AS, Beecher HK. Analgesic activity and toxic effects of acetylmethadol isomers in man. J Pharmacol Exp Ther 1952; 105: 210–5
Fraser HF, Isbell H. Actions and addiction liabilities of alpha-acetylmethadols in man. J Pharmacol Exp Ther 1952; 105: 458–65
Jaffe JH, Schuster CR, Smith BB, et al. Comparison of dl- alpha-acetylmethadol and methadone in the treatment of long-term heroin users: a pilot study. JAMA 1970; 211: 1834–6
Jaffe JH, Senay EC, Schuster CR, et al. Methadyl acetate vs methadone. A double blind study in heroin users. JAMA 1972; 222: 437–42
Billings RE, McMahon RE, Blake DA. 1-Acetylmethadol (LAM) treatment of opiate dependence: plasma and urine levels of two pharmacologically active metabolites. Life Sci 1974; 14: 1437–46
Karp-Gelernter E, Savage C, McCabe OL. Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study. Int J Addict 1982; 17: 805–13
Ling W, Charuvastra VC, Kaim S, et al. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A Veterans Administration cooperative study. Arch Gen Psychiatry 1976; 33: 709–20
Ling W, Klett CJ, Gillis RD. A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. Arch Gen Psychiatry 1978; 35: 345–53
Marcovici M, O’Brien CP, McLellan AT, et al. A clinical, controlled study of 1-α-acetylmethadol in the treatment of narcotic addiction. Am J Psychiatry 1981; 138: 234–6
Savage C, Karp EG, Curran SF, et al. Methadone/LAAM maintenance: a comparison study. Compr Psychiatry 1976; 17: 415–24
Senay EC, Dorus W, Renault PF. Methadyl acetate and methadone. An open comparison. JAMA 1977; 237: 138–42
Wilson BK, Spannagel V, Thompson CP. The use of L-α-acetylmethadol in treatment of heroin addiction: an open study. Int J Addict 1976; 11: 1091–100
Sorensen JL, Hargreaves WA, Weinberg JA. Withdrawal from heroin in three or six weeks. Comparison of methadyl acetate and methadone. Arch Gen Psychiatry 1982; 39: 167–71
Tennant FS, Rawson RA, Pumphrey E, et al. Clinical experience with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). J Subst Abuse Treat 1986; 3: 195–202
Blaine J, Renault P. Rx: three times a week LAAM alternative to methadone. NIDA Res Monogr 1976; 8: 1–9
Judson BA, Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization. Drug Alcohol Depend 1979; 4: 461–6
Ling W, Dorus W, Hargreaves WA, et al. Alternative induction and crossover schedules for methadyl acetate. Arch Gen Psychiatry 1984; 41: 193–9
Judson BA, Goldstein A, Inturrisi CE. Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double blind comparison of gradual and abrupt detoxification. Arch Gen Psychiatry 1983; 40: 834–40
Lewis JW. Buprenorphine. Drug Alcohol Depend 1985; 14: 363–72
Dum J, Blasig J, Herz A. Buprenorphine demonstration of physical dependence liability. Eur J Pharmacol 1981; 70: 293–300
Lewis JW, Ranee MJ, Sanger DJ. The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK, editor. Advances in substance abuse. Greenwich: JAI Press, 1983; 103–54
Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, editor. Pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill Inc., 1990: 513
San L, Cami J, Fernandez T, et al. Double blind assessment of buprenorphine withdrawal in opiate-addicts [letter]. NIDA Res Monogr 1991; 105: 455
Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 531–8
Resnick RB, Galantar M, Pycha C, et al. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 1992; 28: 109–13
Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17: 119–28
Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750–5
Schottenfeld RS, Pakes J, Ziedonis D, et al. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993; 34: 66–74
Bickel WK, Sitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43: 72–8
Fudala PJ, Jaffe JH, Dax EM, et al. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525–34
O’Connor P. Three methods of ambulatory opiate detoxification [letter]. NIDA Res Monogr 1993; 123: 309
Carroll ME, Carmona GN, May SA, et al. Buprenorphine’s effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys. J Pharmacol Exp Ther 1992; 261: 26–37
Mello NK, Mendelson JH, Bree MP, et al. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 1989; 245: 859–62
Mello NK, Lukas SE, Kamien JB, et al. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther 1992; 260: 1185–93
Winger G, Skjoldager P, Woods JH. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 1992; 261: 311–7
Kosten TR, Rounsaville BJ, Kleber HD. A 2.5 year follow-up of cocaine use among treated opioid addicts. Arch Gen Psychiatry 1987; 44: 281–4
Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44: 887–92
Oliveto AH, Kosten TR, Schottenfeld R, et al. Cocaine use in buprenorphine- vs methadone-maintained cocaine users. Am J Addict 1994; 3: 43–8
Schottenfeld RS, Kosten TR, Pakes J, et al. Buprenorphine vs methadone maintenance for combined cocaine and opioid dependence [letter], NIDA Res Monogr 1994; 141: 142
Kosten TR, Oliveto AH, Falcioni J, et al. Desipramine augmentation of buprenorphine for cocaine abuse [letter]. NIDA Res Monogr 1996; 162: 179
Strang J. Abuse of buprenorphine [letter]. Lancet 1985; II: 725
Pickworth WB, Johnson RE, Holicky BA, et al. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 1993; 53: 570–6
Lavelle TL, Hammersley R, Forsyth A. The use of buprenorphine and temazepam by drug injectors. J Addict Dis 1991; 10: 5–14
Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow - an increase [letter]. Br J Addict 1989; 84: 439–41
Gray RF, Ferry A, Jauhar P. Emergence of buprenorphine dependence. Br J Addict 1989; 84: 1373–4
Mendelson J, Jones RT. Assessing new pharmacotherapies for opiate dependence: buprenorphine and naloxone combinations in opiate-dependent volunteers [letter]. Clin Pharmacol Ther 1995; 57: 160
García-Alonso F, Gutierrez M, San L, et al. A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989; 23: 117–21
Capone T, Brahen L, Condren R, et al. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol 1986; 42: 825–33
Christie MJ, Harvey AI. Pharmacological options for management of opioid dependence. Drug Alcohol Rev 1993; 12: 71–80
Mattick R, Hall W, editors. A treatment outline for approaches to opioid dependence: quality assurance in the treatment of drug dependence project. Sydney: National Drug and Alcohol Research Centre. In press
Schwope AD, Howes JF. Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction. NIDA Res Monogr 1976; 4: 13–8
Sullivan MF, Kalkwarf DR. Sustained release of naltrexone from glyceride implants. NIDA Res Monogr 1976; 4: 27–32
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Best, S.E., Oliveto, A.H. & Kosten, T.R. Opioid Addiction. CNS Drugs 6, 301–314 (1996). https://doi.org/10.2165/00023210-199606040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199606040-00005